BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND USP8, FLJ34456, 9101, ENSG00000138592, KIAA0055, P40818, MGC129718, UBPY, HumORF8 AND Treatment
8 results:

  • 1. Cryptic and atypical KMT2A-USP2 and KMT2A-usp8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
    Blackburn PR; Smadbeck JB; Znoyko I; Webley MR; Pitel BA; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Lindsey KG; Schandl CA; Wolff DJ; Peterson JF
    Genes Chromosomes Cancer; 2020 Jul; 59(7):422-427. PubMed ID: 32196814
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
    Lipshultz SE; Miller TL; Lipsitz SR; Neuberg DS; Dahlberg SE; Colan SD; Silverman LB; Henkel JM; Franco VI; Cushman LL; Asselin BL; Clavell LA; Athale U; Michon B; Laverdière C; Schorin MA; Larsen E; Usmani N; Sallan SE;
    Pediatrics; 2012 Dec; 130(6):1003-11. PubMed ID: 23166343
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Predictive factors of internalized and externalized behavioral problems in children treated for acute lymphoblastic leukemia.
    Marcoux S; Robaey P; Krajinovic M; Moghrabi A; Laverdière C
    Pediatr Blood Cancer; 2012 Jun; 58(6):971-7. PubMed ID: 22287274
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).
    Silverman LB; Stevenson KE; O'Brien JE; Asselin BL; Barr RD; Clavell L; Cole PD; Kelly KM; Laverdiere C; Michon B; Schorin MA; Schwartz CL; O'Holleran EW; Neuberg DS; Cohen HJ; Sallan SE
    Leukemia; 2010 Feb; 24(2):320-34. PubMed ID: 20016537
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic leukemia protocol.
    Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
    J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
    Silverman LB; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Arkin S; Declerck L; Cohen HJ; Sallan SE
    Blood; 2001 Mar; 97(5):1211-8. PubMed ID: 11222362
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995).
    Silverman LB; Declerck L; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Lipton JM; Cohen HJ; Sallan SE
    Leukemia; 2000 Dec; 14(12):2247-56. PubMed ID: 11187916
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.
    Waber DP; Carpentieri SC; Klar N; Silverman LB; Schwenn M; Hurwitz CA; Mullenix PJ; Tarbell NJ; Sallan SE
    J Pediatr Hematol Oncol; 2000; 22(3):206-13. PubMed ID: 10864051
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.